[Levobupivacaine in obstetric analgesia and anaesthesia. Where is its place?].
Levobupivacaine, the S-enantiomer of racemic bupivacaine, will be available in Germany in mid-2004. Pharmacological studies demonstrated that, compared to bupivacaine, levobupivacaine has equal local anaesthetic potency with reduced potential for cardiac and CNS toxicity. This review introduces the new long-acting amide local anaesthetic levobupivacaine to the reader and evaluates its place in obstetric analgesia and anaesthesia compared to bupivacaine and ropivacaine.
Bremerich
D H
DH
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt a.M. Bremerich@em.uni-frankfurt.de
Zwissler
B
B
D000328:Adult; D000577:Amides; D015360:Analgesia, Epidural; D016362:Analgesia, Obstetrical; D000773:Anesthesia, Obstetrical; D000779:Anesthetics, Local; D000818:Animals; D002045:Bupivacaine / Q000009:adverse effects / Q000737:chemistry / Q000633:toxicity; D002585:Cesarean Section; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D000077212:Ropivacaine; D013237:Stereoisomerism
D000577:Amides; D000779:Anesthetics, Local; D000077212:Ropivacaine; D002045:Bupivacaine